Impact of CYP2D6 inhibitors on tamoxifen metabolism in breast cancer patients

被引：0
|
作者：
Keller, Denise [1 ]
Medwid, Samantha [2 ]
Schwarz, Ute [2 ]
Legan, Robin [1 ]
Kim, Richard [2 ]
机构：
[1] London Hlth Sci Ctr, London, ON, Canada
[2] Univ Western Ontario, London, ON, Canada
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P0065
引用
收藏
页码：250 / 253
页数：4
相关论文
共 50 条
  • [31] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Jin, Y
    Desta, Z
    Stearns, V
    Ward, B
    Ho, H
    Lee, KH
    Skaar, T
    Storniolo, AM
    Li, L
    Araba, A
    Blanchard, R
    Nguyen, A
    Ullmer, L
    Hayden, J
    Lemler, S
    Weinshilboum, RM
    Rae, JM
    Hayes, DF
    Flockhart, DA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 30 - 39
  • [32] CYP2D6 Polymorphisms and the impact on tamoxifen therapy
    Beverage, Jacob N.
    Sissung, Tristan M.
    Sion, Amy M.
    Danesi, Romano
    Figg, William D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (09) : 2224 - 2231
  • [33] The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
    Ferraldeschi, Roberta
    Newman, William G.
    PHARMACEUTICALS, 2010, 3 (04) : 1122 - 1138
  • [34] Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?
    Borba, Maria A. C. S. M.
    Melo-Neto, Renato P.
    Leitao, Glauber M.
    Castelletti, Carlos H. M.
    Lima-Filho, Jose L.
    Martins, Danyelly B. G.
    PHARMACOGENOMICS, 2016, 17 (06) : 561 - 570
  • [35] CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients
    Barriere, J.
    Formento, J. -L.
    Milano, G.
    Ferrero, J. -M.
    BULLETIN DU CANCER, 2010, 97 (03) : 311 - 320
  • [36] CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
    Sirachainan, Ekaphop
    Jaruhathai, Sureerat
    Trachu, Narumol
    Panvichian, Ravat
    Sirisinha, Thitiya
    Ativitavas, Touch
    Ratanatharathorn, Vorachai
    Chamnanphon, Montri
    Sukasem, Chonlaphat
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 : 149 - 153
  • [37] Dose adjustment of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
    不详
    PHARMACOGENOMICS, 2012, 13 (06) : 647 - 648
  • [38] Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu, Hitoshi
    Sasa, Mitsunori
    Kiyotani, Kazuma
    Mushiroda, Taisei
    Nakamura, Yusuke
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 185 - 193
  • [39] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer Response
    Berry, Donald A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [40] Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen
    de Vasconcelos-Valenca, R. J.
    Melo, M. A.
    Lima, E. M.
    de Sousa, G. V.
    Nazario, A. C.
    da Silva, B. B.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (05) : 700 - 702
12345